Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naïve acute and chronic GVHD, as well as Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC); and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome, as well as a pivotal program for solid tumors with driver activations of FGF/FGFR. Further, it is involved in developing INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer. Additionally, the company develops Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Syros Pharmaceuticals, Inc.; and Innovent Biologics, Inc., as well as BriaCell Therapeutics Corp. for treating cancer. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

3.1 Community Rank

Outperform Votes

Underperform Votes

Community Sentiment

Incyte has received 61.61% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote “Outperform” if you believe INCY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

1.0 Company Ownership

In the past three months, Incyte insiders have sold 1,480,927.80% more of their company's stock than they have bought. Specifically, they have bought $205.00 in company stock and sold $3,036,107.00 in company stock.

Miscellaneous

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

Incyte (NASDAQ:INCY) Frequently Asked Questions

How has Incyte's stock been impacted by COVID-19 (Coronavirus)?

Incyte's stock was trading at $71.90 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, INCY shares have increased by 30.1% and is now trading at $93.51. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Incyte?

22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There are currently 9 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Incyte.

When is Incyte's next earnings date?

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) released its earnings results on Tuesday, May, 5th. The biopharmaceutical company reported ($2.86) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by $3.17. The biopharmaceutical company earned $568.51 million during the quarter, compared to analysts' expectations of $553.24 million. Incyte had a negative return on equity of 12.81% and a negative net margin of 16.87%. Incyte's revenue was up 14.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.62 EPS. View Incyte's earnings history.

What price target have analysts set for INCY?

22 analysts have issued 12 month price targets for Incyte's shares. Their forecasts range from $79.00 to $124.00. On average, they expect Incyte's share price to reach $100.65 in the next twelve months. This suggests a possible upside of 7.6% from the stock's current price. View analysts' price targets for Incyte.

Has Incyte been receiving favorable news coverage?

News stories about INCY stock have been trending extremely negative recently, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Incyte earned a coverage optimism score of -5.0 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news aboutIncyte.

Are investors shorting Incyte?

Incyte saw a increase in short interest during the month of April. As of April 30th, there was short interest totaling 7,230,000 shares, an increase of 17.6% from the April 15th total of 6,150,000 shares. Based on an average daily volume of 2,020,000 shares, the short-interest ratio is currently 3.6 days. Approximately 3.4% of the company's shares are sold short. View Incyte's Current Options Chain.

Which institutional investors are buying Incyte stock?

INCY stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, MERIAN GLOBAL INVESTORS UK Ltd, Camber Capital Management LP, NWQ Investment Management Company LLC, First Trust Advisors LP, Eaton Vance Management, Sector Gamma AS, and PGGM Investments. Company insiders that have bought Incyte stock in the last two years include Bros Advisors Lp Baker, and Jean Jacques Bienaime. View insider buying and selling activity for Incyte.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $93.51.

How big of a company is Incyte?

Incyte has a market capitalization of $20.33 billion and generates $2.16 billion in revenue each year. The biopharmaceutical company earns $446.91 million in net income (profit) each year or $2.23 on an earnings per share basis. Incyte employs 1,456 workers across the globe.